Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stephen Caltabiano"'
Autor:
Christine K. Bailey, Stephen Caltabiano, Alexander R. Cobitz, Chun Huang, Kelly M. Mahar, Vickas V. Patel
Publikováno v:
BMC Nephrology, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clinical studies to date,
Externí odkaz:
https://doaj.org/article/27bc2670a74349538c5d727bfabca1f7
Autor:
Masanori Yamada, Kelly M. Mahar, Stephen Caltabiano, Hirofumi Ogura, Tomohiro Onoue, Akira Wakamatsu, Minori Osamura, Yotaro Numachi
Publikováno v:
Clinical Pharmacology in Drug Development
Daprodustat is a prolyl hydroxylase inhibitor that stimulates erythropoiesis in a manner similar to the natural response to hypoxia, whereby inhibition of hypoxia inducible factor (HIF) prolyl‐4‐hydroxylases by daprodustat ultimately results in i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6485ed1b5333617548bea8577447ee
https://doi.org/10.1002/cpdd.793
https://doi.org/10.1002/cpdd.793
Autor:
Alexander R. Cobitz, Christine K Bailey, Kelly M. Mahar, Vickas V. Patel, Stephen Caltabiano, Chun Huang
Publikováno v:
BMC Nephrology, Vol 20, Iss 1, Pp 1-12 (2019)
BMC Nephrology
BMC Nephrology
Background Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clinical studies to date, daprodust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09fc1afa7cb3093c224262a4a6b52d3
http://link.springer.com/article/10.1186/s12882-019-1547-z
http://link.springer.com/article/10.1186/s12882-019-1547-z
Autor:
Kelly M. Mahar, Stephen Caltabiano, Olivia Burns, Borut Cizman, Alexander R. Cobitz, Gulyeter Serbest, Brendan M Johnson, Bandi Ramanjineyulu
Publikováno v:
Clinical Kidney Journal
Background Current therapies for anemia of chronic kidney disease (CKD) include administration of supplemental iron (intravenous and/or oral), blood transfusions and replacement of erythropoietin through the administration of recombinant human erythr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c63c094a35a11466d31e81bdb66559
http://europepmc.org/articles/PMC6768310
http://europepmc.org/articles/PMC6768310
Autor:
Alexander R. Cobitz, Kelly M. Mahar, Liangfu Chen, Bandi Ramanjineyulu, Frans van den Berg, Adrian Pereira, Susan Andrews, Graeme Young, Alistair C. Lindsay, Stephen Caltabiano
Publikováno v:
Clinical pharmacology in drug development. 10(12)
Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease. This phase 1, nonrandomized, 2-period, crossover study in 6 healthy men characterized the absorption,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3bafca519b05b1ab0f6a9c4c196697
https://pubmed.ncbi.nlm.nih.gov/34713596
https://pubmed.ncbi.nlm.nih.gov/34713596
Autor:
Nandita Biswas, Alexander R. Cobitz, Chun Huang, Amy Meadowcroft, Borut Cizman, Stephen Caltabiano, Julian Jenkins
Publikováno v:
Nephrology Dialysis Transplantation. 34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8928c3c9bc61ed17367d7fa73a7ec276
https://doi.org/10.1093/ndt/gfz103.sp343
https://doi.org/10.1093/ndt/gfz103.sp343
Publikováno v:
Clinical Therapeutics. 37:1541-1554
Purpose Retosiban is a small molecule oxytocin receptor antagonist that is under evaluation in clinical studies for treatment of spontaneous preterm labor. A Thorough QT/QTc study was conducted to evaluate the effect of retosiban on cardiac repolariz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a98bfbcf28ff251548f9afd01c67320b
https://doi.org/10.1016/j.clinthera.2015.05.007
https://doi.org/10.1016/j.clinthera.2015.05.007
Publikováno v:
Clinical Pharmacology in Drug Development. 3:109-117
Anemia, a frequent complication of chronic kidney disease, is most commonly treated with recombinant human erythropoiesis-stimulating agents. Oral administration of GSK1278863, a prolyl hydroxylase inhibitor, results in the accumulation of hypoxia-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fd9f7555e07fa5c13428c1d03df5b13
https://doi.org/10.1002/cpdd.83
https://doi.org/10.1002/cpdd.83
Publikováno v:
Clinical pharmacology in drug development. 7(1)
This study characterized the pharmacokinetics, safety, and tolerability of retosiban in healthy, nonpregnant Japanese women prior to the enrollment of Japanese women in preterm labor in phase 3 trials. This study had 2 cohorts. Cohort 1 was a double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68e1ad029d10013719cf6e3f9091e9d
https://pubmed.ncbi.nlm.nih.gov/28419732
https://pubmed.ncbi.nlm.nih.gov/28419732
Autor:
Jon L. Collins, Gul Serbest, Ramiya Ravindranath, Alexander R. Cobitz, Stephen Caltabiano, Lisa A. Morgan, Deborah A. Smith
Publikováno v:
Clinical pharmacology in drug development. 6(6)
Daprodustat (GSK1278863) is a prolyl hydroxylase inhibitor in phase 3 clinical studies for the treatment of anemia associated with chronic kidney disease. This study was conducted to evaluate the effect of daprodustat on cardiac repolarization and en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e5d5d621850073f27829bcb9dbd988
https://pubmed.ncbi.nlm.nih.gov/28419747
https://pubmed.ncbi.nlm.nih.gov/28419747